PharmacoEconomics & Outcomes News

, Volume 803, Issue 1, pp 7–7 | Cite as

Cabozantinib cost effective for advanced RCC in England

Clinical study


  1. Meng J, et al. Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England. ClinicoEconomics and Outcomes Research : 23 Apr 2018. Available from: URL:

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations